Trade SCYNEXIS, Inc. - SCYX CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.85 |
Open | 1.83 |
1-Year Change | -37.54% |
Day's Range | 1.83 - 1.95 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
May 10, 2024 | 1.92 | 0.06 | 3.23% | 1.86 | 1.95 | 1.83 |
May 9, 2024 | 1.85 | -0.04 | -2.12% | 1.89 | 1.89 | 1.78 |
May 8, 2024 | 1.81 | 0.02 | 1.12% | 1.79 | 1.83 | 1.76 |
May 7, 2024 | 1.82 | 0.12 | 7.06% | 1.70 | 1.88 | 1.69 |
May 6, 2024 | 1.71 | -0.04 | -2.29% | 1.75 | 1.75 | 1.70 |
May 3, 2024 | 1.75 | -0.03 | -1.69% | 1.78 | 1.82 | 1.68 |
May 2, 2024 | 1.75 | 0.05 | 2.94% | 1.70 | 1.76 | 1.68 |
May 1, 2024 | 1.70 | 0.08 | 4.94% | 1.62 | 1.71 | 1.62 |
Apr 30, 2024 | 1.67 | -0.09 | -5.11% | 1.76 | 1.76 | 1.66 |
Apr 29, 2024 | 1.79 | 0.27 | 17.76% | 1.52 | 1.90 | 1.52 |
Apr 26, 2024 | 1.52 | 0.07 | 4.83% | 1.45 | 1.55 | 1.40 |
Apr 25, 2024 | 1.43 | -0.03 | -2.05% | 1.46 | 1.46 | 1.38 |
Apr 24, 2024 | 1.47 | -0.07 | -4.55% | 1.54 | 1.55 | 1.46 |
Apr 23, 2024 | 1.53 | 0.12 | 8.51% | 1.41 | 1.57 | 1.41 |
Apr 22, 2024 | 1.42 | -0.01 | -0.70% | 1.43 | 1.45 | 1.40 |
Apr 19, 2024 | 1.42 | 0.04 | 2.90% | 1.38 | 1.43 | 1.36 |
Apr 18, 2024 | 1.38 | -0.02 | -1.43% | 1.40 | 1.44 | 1.37 |
Apr 17, 2024 | 1.40 | 0.02 | 1.45% | 1.38 | 1.43 | 1.34 |
Apr 16, 2024 | 1.38 | -0.02 | -1.43% | 1.40 | 1.43 | 1.38 |
Apr 15, 2024 | 1.43 | -0.03 | -2.05% | 1.46 | 1.48 | 1.40 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
SCYNEXIS, Inc. Company profile
About SCYNEXIS Inc
SCYNEXIS, Inc. is a biotechnology company. The Company is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous oral agent for multiple fungal indications in both the community and hospital settings. It has received the acceptance letter from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for oral ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). The FDA has conditionally approved Brexafemme as the brand name for oral ibrexafungerp for vaginal yeast infections. It is also continuing late-stage clinical development for the prevention of recurrent VVC, as well as the treatment of life-threatening invasive fungal infections in hospitalized patients.
Financial summary
BRIEF: For the nine months ended 30 September 2021, SCYNEXIS Inc revenues increased from $0K to $12.6M. Net loss decreased 71% to $3.6M. Revenues reflect Revenue increase from $0K to $12.1M. Lower net loss reflects Warrant liabilities fair value adjustmen increase from $16.1M to $35.4M (income), Research and development - Balancing decrease of 40% to $15.6M (expense), Other expense decrease from $622K (expense) to $0K.
News
Stock market crash: how far can the S&P 500 go?
After a remarkably strong first quarter, the US stock market pulled back in April for the first time since October last year.
11:46, 10 May 2024Bank of England preview: possible rate cut in summer?
The Bank of England (BoE) is widely expected to keep interest rates unchanged when it meets later this week. Data from Reuters shows a 90% chance of no change to the current rate of 5.25%, but the central bank will need to decide whether to change the messaging about rate cuts this year as traders will be paying close attention to any rate-cut clues.
12:39, 8 May 2024We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com